Home > Plasma Biomarkers to Determine Severity of Lung Function in CF
Cystic Fibrosis

Plasma Biomarkers to Determine Severity of Lung Function in CF

Published Online: September 2nd 2015

During the 36th Annual European Cystic Fibrosis Conference held in Lisbon, Drs. Peter Mogayzel and Kenneth Olivier, Staff Clinician at the National Institute of Allergy and Infectious Diseases in Bethesda, Maryland, discuss importance of mycobacterium in CF. Dr. Olivier also discusses the new NTM guidelines that are being developed.

Related Videos In Cystic Fibrosis
  • Journal articles and more to your inbox


    Get the latest clinical insights from touchRESPIRATORY

    Sign me up!
    Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down crosscrossdownloademailexclaimationfeedbackfiltergraph-arrowlinkmenumore_dots padlock person play-colourAsset 1podcastprinter search share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrow